Home › Companies › Palvella Therapeutics, Inc. › 2025-2026

Palvella Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Palvella Therapeutics, Inc.’s Form 8-K, filed 2026-06-16 (Item 5.07 on EDGAR). Page generated 02 October 2026.

9Reported items
192Asset managers
1,810Fund votes
2026-06-10Meeting date

Proxy season: 2025-2026

Explore Palvella Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Palvella Therapeutics, Inc.

These tallies are Palvella Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-16 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Palvella Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-10
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: George M. Jenkins	9,907,220	--	--	268,834	1,401,415	Majority: yes
Elect Director: Todd C. Davis	8,321,303	--	--	1,854,751	1,401,415	Majority: yes
Elect Director: John Doux, M.D.	9,958,528	--	--	217,526	1,401,415	Majority: yes
Proposal 2 - Ratification of Independent Registered Public Accountant.	11,557,687	13,216	6,566	--	--	Majority: yes
Proposal 3 - Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2025.	10,008,180	160,717	7,157	--	1,401,415	Majority: yes
Proposal 5: Approval of an amendment to the Palvella Therapeutics, Inc	7,692,709	2,475,470	7,875	--	1,401,415	Majority: yes
Proposal 6: Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5	7,649,243	2,519,068	7,743	--	1,401,415	Majority: yes

Source: Palvella Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-16 — read the filing on EDGAR.

How asset managers voted at the Palvella Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 192 asset managers that disclosed a Palvella Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Palvella Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 10,008,180AGAINST: 160,717

Palvella Therapeutics, Inc.’s own tally for this item (“Proposal 3 - Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2025.”): 10,008,180 for, 160,717 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 14,313,659 outstanding shares: 70% for, 1% against (71% of the company cast a for/against vote).

The 191 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 98%

FOR: 98.4%AGAINST: 1.5%ABSTAIN: 0.1%

Largest asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Palvella Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
MONTANOVA CAPITAL, LLC	1,173,366	0	For
BVF INC/IL	960,989	0	For
Frazier Life Sciences Management, L.P.	882,400	0	For
Federated Hermes	816,430	0	For
First Light Asset Management, LLC	750,908	0	For
T. Rowe Price	695,316	0	For
Vanguard	642,603	0	For
State Street	402,308	1,939	For
AllianceBernstein	365,965	0	For
BlackRock	292,711	421	For
JENNISON ASSOCIATES LLC	275,465	712	For
Siren, L.L.C.	247,192	0	For
MUTUAL FUND SERIES TRUST	231,484	0	For
PRIMECAP MANAGEMENT CO/CA/	195,230	0	For
PRIMECAP Odyssey Funds	163,475	0	For
FRONTIER CAPITAL MANAGEMENT CO LLC	156,367	5,681	For
Woodline Partners LP	148,216	0	For
ORBIMED ADVISORS LLC	123,643	0	For
MPM BioImpact LLC	117,806	0	For
Prudential/PGIM	110,410	0	For
Artisan	102,703	0	For
EMERALD ADVISERS, LLC	87,399	0	For
Aberdeen	81,081	0	For
Neuberger Berman	76,733	0	For
Fidelity	72,697	0	For

Showing the 25 largest of 191 asset managers. See all 191 in the interactive database.

2. APPROVAL, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 16%ONE YEAR 43%1 YEAR 30%9%

The 186 asset managers below cast 99.9% of the shares they voted on this item FOR (1,699,991 for, 35 against).

FOR: 1,699,991 (16.2%)AGAINST: 35 (0.0%)ABSTAIN: 6,070 (0.1%)ONE YEAR: 4,513,581 (43.0%)1 YEAR: 3,121,092 (29.8%)1-YR: 960,989 (9.2%)1-YEAR: 148,369 (1.4%)3 YEARS: 39,288 (0.4%)THREE YEARS: 218 (0.0%)1.0: 21 (0.0%)

Largest asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID T” at Palvella Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
MONTANOVA CAPITAL, LLC	0	One Year
BVF INC/IL	0	1-Yr
Frazier Life Sciences Management, L.P.	882,400	For
Federated Hermes	0	1 Year
First Light Asset Management, LLC	750,908	For
T. Rowe Price	0	One Year
Vanguard	0	One Year
State Street	0	One Year
AllianceBernstein	0	One Year
BlackRock	0	1 Year
JENNISON ASSOCIATES LLC	0	1 Year
Siren, L.L.C.	0	1 Year
MUTUAL FUND SERIES TRUST	0	One Year
PRIMECAP MANAGEMENT CO/CA/	0	1 Year
PRIMECAP Odyssey Funds	0	1 Year
FRONTIER CAPITAL MANAGEMENT CO LLC	0	1 Year
Woodline Partners LP	0	1-Year
ORBIMED ADVISORS LLC	0	1 Year
MPM BioImpact LLC	0	1 Year
Prudential/PGIM	0	One Year
Artisan	0	One Year
EMERALD ADVISERS, LLC	0	1 Year
Aberdeen	0	One Year
Neuberger Berman	0	1 Year
Fidelity	0	One Year

Showing the 25 largest of 186 asset managers. See all 186 in the interactive database.

3. APPROVAL OF AN AMENDMENT TO THE 2024 EQUITY INCENTIVE PLAN TO INCREASE THE AUTHORIZED SHARES ISSUABLE UNDER THE 2024 PLAN BY 750,000 SHARES.

COMPENSATION

66% fund support · no official result

FOR 66%AGAINST 34%

The 62 asset managers below cast 66% of the shares they voted on this item FOR (2,507,643 for, 1,298,797 against).

FOR: 2,507,643 (65.8%)AGAINST: 1,298,797 (34.1%)ABSTAIN: 6,070 (0.2%)

Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO THE 2024 EQUITY INCENTIVE PLAN TO INCREASE THE AUTHORIZED SHARES ISSUABLE UNDER TH” at Palvella Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
First Light Asset Management, LLC	750,908	0	0	For
Vanguard	91,586	471,004	0	Against
Federated Hermes	408,215	0	0	For
T. Rowe Price	306,933	0	0	For
State Street	132	292,803	0	Against
MUTUAL FUND SERIES TRUST	231,484	0	0	For
BlackRock	194,278	0	0	For
PRIMECAP Odyssey Funds	163,475	0	0	For
AllianceBernstein	0	137,145	0	Against
Prudential/PGIM	109,205	0	0	For
Principal	39,911	31,961	0	For
RBB FUND, INC.	65,909	0	0	For
Legg Mason	0	56,480	0	Against
APIS CAPITAL ADVISORS, LLC	50,000	0	0	For
Fidelity	4,406	40,539	0	Against
Calamos	33,071	0	0	For
Royce	0	31,500	0	Against
Neuberger Berman	0	24,153	0	Against
Invesco	0	23,629	0	Against
Charles Schwab	0	22,955	0	Against
Jackson National	0	20,757	0	Against
TIAA	19,664	0	0	For
Equitable	14,704	4,860	0	For
Brighthouse	7,793	2,572	6,070	For
CARILLON SERIES TRUST	0	15,353	0	Against

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

4. Election of three director nominees to serve as Class III directors whose term will expire in 2029: George M. Jenkins

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 9,907,220WITHHELD: 268,834

Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: George M. Jenkins”): 9,907,220 for, 268,834 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 14,313,659 outstanding shares: 69% for, 2% withheld (71% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (2,899,920 for, 0 against).

FOR 96%

FOR: 2,899,920 (96.2%)ABSTAIN: 113,110 (3.8%)

Largest asset managers voting on “Election of three director nominees to serve as Class III directors whose term will expire in 2029: George M. ” at Palvella Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	562,168	422	For
Federated Hermes	408,215	0	For
T. Rowe Price	306,933	0	For
State Street	292,935	0	For
MUTUAL FUND SERIES TRUST	231,484	0	For
BlackRock	194,278	0	For
PRIMECAP Odyssey Funds	163,475	0	For
AllianceBernstein	137,145	0	For
Prudential/PGIM	109,205	0	For
Principal	31,961	39,911	Abstain
RBB FUND, INC.	0	65,909	Abstain
Legg Mason	56,480	0	For
Fidelity	44,945	0	For
Calamos	33,071	0	For
Royce	31,500	0	For
Neuberger Berman	24,153	0	For
Invesco	23,629	0	For
Charles Schwab	22,955	0	For
Jackson National	20,757	0	For
TIAA	19,664	0	For
Equitable	19,564	0	For
Brighthouse	10,365	6,070	For
CARILLON SERIES TRUST	15,353	0	For
Advisors' Inner Circle Fund III	12,371	0	For
Victory Capital	11,403	0	For

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

5. Election of three director nominees to serve as Class III directors whose term will expire in 2029: John Doux, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 9,958,528WITHHELD: 217,526

Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: John Doux, M.D.”): 9,958,528 for, 217,526 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 14,313,659 outstanding shares: 70% for, 2% withheld (71% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (2,901,140 for, 0 against).

FOR 96%

FOR: 2,901,140 (96.3%)ABSTAIN: 111,890 (3.7%)

Largest asset managers voting on “Election of three director nominees to serve as Class III directors whose term will expire in 2029: John Doux,” at Palvella Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	562,590	0	For
Federated Hermes	408,215	0	For
T. Rowe Price	306,933	0	For
State Street	292,935	0	For
MUTUAL FUND SERIES TRUST	231,484	0	For
BlackRock	194,278	0	For
PRIMECAP Odyssey Funds	163,475	0	For
AllianceBernstein	137,145	0	For
Prudential/PGIM	109,205	0	For
Principal	31,961	39,911	Abstain
RBB FUND, INC.	0	65,909	Abstain
Legg Mason	56,480	0	For
Fidelity	44,945	0	For
Calamos	33,071	0	For
Royce	31,500	0	For
Neuberger Berman	24,153	0	For
Invesco	23,629	0	For
Charles Schwab	22,955	0	For
Jackson National	20,757	0	For
TIAA	19,664	0	For
Equitable	19,564	0	For
Brighthouse	10,365	6,070	For
CARILLON SERIES TRUST	15,353	0	For
Advisors' Inner Circle Fund III	12,371	0	For
Victory Capital	11,403	0	For

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

6. Election of three director nominees to serve as Class III directors whose term will expire in 2029: Todd C. Davis

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD 18%

FOR: 8,321,303WITHHELD: 1,854,751

Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: Todd C. Davis”): 8,321,303 for, 1,854,751 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 14,313,659 outstanding shares: 58% for, 13% withheld (71% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (1,826,990 for, 0 against).

FOR 61%ABSTAIN 39%

FOR: 1,826,990 (60.6%)ABSTAIN: 1,186,040 (39.4%)

Largest asset managers voting on “Election of three director nominees to serve as Class III directors whose term will expire in 2029: Todd C. Da” at Palvella Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	562,164	426	For
Federated Hermes	0	408,215	Abstain
T. Rowe Price	306,933	0	For
State Street	600	292,335	Abstain
MUTUAL FUND SERIES TRUST	231,484	0	For
BlackRock	194,278	0	For
PRIMECAP Odyssey Funds	163,475	0	For
AllianceBernstein	0	137,145	Abstain
Prudential/PGIM	109,205	0	For
Principal	0	71,872	Abstain
RBB FUND, INC.	0	65,909	Abstain
Legg Mason	56,480	0	For
Fidelity	17,832	27,113	Abstain
Calamos	33,071	0	For
Royce	0	31,500	Abstain
Neuberger Berman	0	24,153	Abstain
Invesco	23,629	0	For
Charles Schwab	22,955	0	For
Jackson National	20,757	0	For
TIAA	0	19,664	Abstain
Equitable	14,704	4,860	For
Brighthouse	7,793	8,642	Abstain
CARILLON SERIES TRUST	0	15,353	Abstain
Advisors' Inner Circle Fund III	12,371	0	For
Victory Capital	0	11,403	Abstain

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

7. APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEETING TO APPROVE PROPOSAL 5.

CORPORATE GOVERNANCEMajority of the votes cast: yes

75% Majority: yes · of votes cast

FOR 75%AGAINST 25%

FOR: 7,649,243AGAINST: 2,519,068

Palvella Therapeutics, Inc.’s own tally for this item (“Proposal 6: Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5”): 7,649,243 for, 2,519,068 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 14,313,659 outstanding shares: 53.4% for, 18% against (71% of the company cast a for/against vote).

The 59 asset managers below cast 52.3% of the shares they voted on this item FOR (1,571,298 for, 1,434,082 against).

FOR 52.2%AGAINST 47.6%

FOR: 1,571,298 (52.2%)AGAINST: 1,434,082 (47.6%)ABSTAIN: 6,070 (0.2%)

Largest asset managers voting on “APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEET” at Palvella Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	92,451	470,139	0	Against
Federated Hermes	408,215	0	0	For
T. Rowe Price	0	306,933	0	Against
State Street	600	292,335	0	Against
MUTUAL FUND SERIES TRUST	231,484	0	0	For
BlackRock	194,278	0	0	For
PRIMECAP Odyssey Funds	163,475	0	0	For
AllianceBernstein	137,145	0	0	For
Prudential/PGIM	109,205	0	0	For
Principal	71,364	508	0	For
RBB FUND, INC.	65,909	0	0	For
Legg Mason	0	56,480	0	Against
Fidelity	4,406	40,539	0	Against
Calamos	33,071	0	0	For
Royce	0	31,500	0	Against
Neuberger Berman	0	24,153	0	Against
Invesco	23,629	0	0	For
Charles Schwab	0	22,955	0	Against
Jackson National	0	20,757	0	Against
TIAA	0	19,664	0	Against
Equitable	17,289	2,275	0	For
Brighthouse	0	10,365	6,070	Against
CARILLON SERIES TRUST	0	15,353	0	Against
Advisors' Inner Circle Fund III	7,011	5,360	0	For
Victory Capital	0	11,403	0	Against

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

8. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE 2026 FISCAL YEAR.

AUDIT-RELATEDMajority of the votes cast: yes

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 11,557,687AGAINST: 13,216

Palvella Therapeutics, Inc.’s own tally for this item (“Proposal 2 - Ratification of Independent Registered Public Accountant.”): 11,557,687 for, 13,216 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 14,313,659 outstanding shares: 81% for, 0.1% against (81% of the company cast a for/against vote).

The 59 asset managers below cast 99.9% of the shares they voted on this item FOR (3,005,368 for, 12 against).

FOR 99.7%

FOR: 3,005,368 (99.8%)AGAINST: 12 (0.0%)ABSTAIN: 6,070 (0.2%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at Palvella Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	562,590	0	0	For
Federated Hermes	408,215	0	0	For
T. Rowe Price	306,933	0	0	For
State Street	292,923	12	0	For
MUTUAL FUND SERIES TRUST	231,484	0	0	For
BlackRock	194,278	0	0	For
PRIMECAP Odyssey Funds	163,475	0	0	For
AllianceBernstein	137,145	0	0	For
Prudential/PGIM	109,205	0	0	For
Principal	71,872	0	0	For
RBB FUND, INC.	65,909	0	0	For
Legg Mason	56,480	0	0	For
Fidelity	44,945	0	0	For
Calamos	33,071	0	0	For
Royce	31,500	0	0	For
Neuberger Berman	24,153	0	0	For
Invesco	23,629	0	0	For
Charles Schwab	22,955	0	0	For
Jackson National	20,757	0	0	For
TIAA	19,664	0	0	For
Equitable	19,564	0	0	For
Brighthouse	10,365	0	6,070	For
CARILLON SERIES TRUST	15,353	0	0	For
Advisors' Inner Circle Fund III	12,371	0	0	For
Victory Capital	11,403	0	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

9. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

ONE YEAR 99.7%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR: 2,136 (99.8%)1 YEAR: 5 (0.2%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Palvella Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
FORUM FUNDS	0	0	0	0	One Year
APG Asset Management US Inc.	0	0	0	0	One Year
Coyle Financial Counsel LLC	0	0	0	0	1 Year

Largest Palvella Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Palvella Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 14,313,659 shares outstanding at the time of that meeting.

Top Palvella Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	MONTANOVA CAPITAL, LLC	8.20%
2	BVF INC/IL	6.71%
3	Frazier Life Sciences Management, L.P.	6.16%
4	Federated Hermes	5.70%
5	First Light Asset Management, LLC	5.25%
6	T. Rowe Price	4.86%
7	Vanguard	4.49%
8	State Street	2.82%
9	AllianceBernstein	2.56%
10	BlackRock	2.05%

Reported Palvella Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Palvella Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Wesley H. Kaupinen	7.89%	DEF14A
PRUDENTIAL FINANCIAL INC	6.72%	13G
Jennison Associates LLC	6.71%	13G
Entities affiliated with First Light Asset Management, LLC	6.20%	DEF14A
Entities affiliated with Biotechnology Value Fund, L.P.	6.14%	DEF14A
Entities affiliated with Suvretta Capital Management, LLC	5.75%	DEF14A
Entities affiliated with Frazier Life Sciences Public Fund, L.P.	5.05%	DEF14A
Frazier Life Sciences Public Fund, L.P.	4.93%	13G
BlackRock	4.80%	13F
BVF PARTNERS L P/IL	4.70%	13G

Percentages above are of 14,313,659 shares outstanding, as reported by Palvella Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Palvella Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Palvella Therapeutics, Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 192 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,810 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Palvella Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-16.

Palvella Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).